bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.950
-0.023 (-2.35%)
Dec 24, 2024, 12:50 PM EST - Market closed
Company Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Sep 1, 2022 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Maria Zannes |
Contact Details
Address: 22211 West Interstate 10, Suite 1206 San Antonio, Texas 78257 United States | |
| Phone | 210 698 5334 |
| Website | bioaffinitytech.com |
Stock Details
| Ticker Symbol | BIAF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.13 |
| CIK Code | 0001712762 |
| CUSIP Number | 09076W109 |
| ISIN Number | US09076W1099 |
| Employer ID | 46-5211056 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maria Zannes | Chief Executive Officer |
| J. Edwards | Chief Financial Officer |
| Xavier Reveles | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 23, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 9, 2024 | 424B3 | Prospectus |
| Dec 6, 2024 | EFFECT | Notice of Effectiveness |
| Nov 27, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 22, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | 424B3 | Prospectus |
| Nov 22, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2024 | 10-Q | Quarterly Report |